Antibody therapies and their challenges in the treatment of age-related macular degeneration

European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V
Cornelia Volz, Diana Pauly

Abstract

Age-related macular degeneration (AMD) is the leading cause of vision loss in the western world. This multifactorial disease results from the combined contributions of age, environment and genetic predisposition. Antibody-based treatment of late-stage neovascular AMD with inhibitors of vascular endothelial growth factor has had great success, which is now the goal for currently untreatable AMD manifestations. The existence of an immune-privileged environment in the eye supports the feasibility of localized antibody therapy. Many different antibodies against various targets are being developed for the treatment of AMD, which reflects the etiological complexity of the disease. This review provides an overview of 19 potential therapeutic antibodies targeting angiogenesis, the complement system, inflammation or amyloid beta deposition in the eye. It summarizes the immunoglobulin structure, the specific target and study outcomes for each approach. The latter include beneficial results or adverse effects in AMD models and patients. Finally, this article discusses the challenges in the development of antibody-based drugs to treat degenerative processes in the posterior eye. In spite of these difficulties, to date, the following four a...Continue Reading

References

Dec 1, 1978·The Journal of Experimental Medicine·P H Lesavre, H J Müller-Eberhard
Sep 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·C F BarbasS J Benkovic
Aug 15, 1991·Nature·T ClacksonG Winter
Aug 15, 1991·Gene·F BreitlingM Little
Aug 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·M Fràter-SchröderP Böhlen
Dec 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·C QueenT A Waldmann
Feb 14, 1985·The New England Journal of Medicine·J E VolanakisJ H Galla
Dec 13, 1984·Nature·G L BoulianneM J Shulman
Nov 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·S L MorrisonV T Oi
Dec 1, 1995·Archives of Ophthalmology·L P AielloM A Iwamoto
Jan 1, 1995·International Reviews of Immunology·N Lonberg, D Huszar
Jun 20, 1995·Proceedings of the National Academy of Sciences of the United States of America·Z ZhangE Ruoslahti
Oct 1, 1995·Current Opinion in Biotechnology·A Jakobovits
Aug 2, 2000·Ophthalmology·M R VanNewkirkC A McCarty
Oct 23, 2002·Proceedings of the National Academy of Sciences of the United States of America·John W CrabbJoe G Hollyfield
Apr 26, 2003·Investigative Ophthalmology & Visual Science·Timothy L JacksonJohn Marshall
Sep 10, 2003·Archives of Ophthalmology·Shikun HeDavid R Hinton
Dec 12, 2003·Nature Reviews. Immunology·J Wayne Streilein
Mar 12, 2004·American Journal of Ophthalmology·Hans E Grossniklaus, W Richard Green
May 12, 2004·Nature Reviews. Drug Discovery·Napoleone FerraraWilliam Novotny
Oct 20, 2004·Retina·Rama D JagerEmmett T Cunningham
Mar 12, 2005·Science·Jonathan L HainesMargaret A Pericak-Vance
Mar 12, 2005·Science·Albert O EdwardsLindsay A Farrer
Apr 13, 2005·Autoimmunity Reviews·Fabiola AtzeniFranco Capsoni
Jan 13, 2006·Trends in Molecular Medicine·Shannon E GardellJerold Chun
Sep 9, 2006·Experimental Eye Research·Xuan ShiAntonia M Joussen
Sep 12, 2007·Archives of Ophthalmology·Jeffrey L OlsonNaresh Mandava
Oct 27, 2007·Investigative Ophthalmology & Visual Science·Bärbel RohrerGary S Gilkeson
Jan 29, 2008·Nature Medicine·Joe G HollyfieldVictor L Perez
Sep 11, 2008·Journal of Cellular Physiology·Bing XiePeter A Campochiaro
Feb 13, 2009·American Journal of Ophthalmology·Panagiotis G TheodossiadisGeorge P Theodossiadis
Mar 28, 2009·Investigative Ophthalmology & Visual Science·Hiroyuki NomotoTetsuya Baba
Jun 11, 2009·Journal of Lipid Research·Nicole O'BrienRoger Sabbadini
Oct 10, 2009·Proceedings of the National Academy of Sciences of the United States of America·Jonathan M WojciakTom Huxford
Dec 2, 2009·Annual Review of Immunology·Claudia KemperDennis E Hourcade
Dec 10, 2009·Retina·Monica GigantiNaomi Falk

❮ Previous
Next ❯

Citations

Mar 10, 2016·Seminars in Ophthalmology·Mira M Sachdeva, Dean Eliott
Aug 24, 2016·Frontiers in Neurology·Ambra MasuzzoSlavica Krantic
Nov 29, 2016·Expert Opinion on Drug Delivery·Taís GratieriYogeshvar N Kalia
Dec 2, 2017·Nature Reviews. Drug Discovery·Paul J Carter, Greg A Lazar
Aug 31, 2019·Scientific Reports·Jaimie Hoh KamGlen Jeffery
Mar 30, 2019·Investigative Ophthalmology & Visual Science·Leah A OwenMargaret M DeAngelis
Jun 19, 2019·Nature Chemical Biology·Keith JendzaGregory A Michaud
Dec 30, 2020·International Journal of Molecular Sciences·Emilie Grarup JensenThomas J Corydon
Mar 12, 2021·Pharmacology Research & Perspectives·María L FormicaSantiago D Palma
Jun 24, 2021·Investigative Ophthalmology & Visual Science·John T DemirsSha-Mei Liao
Jun 30, 2021·British Journal of Pharmacology·Jeannette Rudzitis-AuthMatthias W Laschke
Aug 10, 2021·Journal of Immunology Research·Shuqi QinYanling Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.